source
- Spyre’s rheumatoid arthritis plan toppled by subpar TL1A dataPhase 2 data on Spyre Therapeutics’ anti-TL1A antibody SPY072 in rheumatoid arthritis have fallen short of expectations, prompting the biotech to deprioritize monotherapy development in the indicat…Fierce Biotech · 9h ago↗ source
- Sentivera secures up to $1.5 billion licensing deal for inflammatory disease candidateSentivera, a biotech startup formed by investors behind Metsera, announced a licensing agreement with Shanghai-listed Haisco Pharmaceutical. Under the deal, Sentivera will pay Haisco $40 million u…